Becampanel

Becampanel

Systematic (IUPAC) name
({[(2,3-Dihydroxy-7-nitro-5-quinoxalinyl)methyl]amino}methyl)phosphonic acid
Identifiers
CAS Number	188696-80-2
ATC code	None
PubChem	CID 5491960
ChemSpider	4590791
Chemical data
Formula	C10H11N4O7P
Molar mass	330.191 g/mol
SMILES c1c(cc2c(c1CNCP(=O)(O)O)[nH]c(=O)c(=O)[nH]2)[N+](=O)[O-]
InChI InChI=1S/C10H11N4O7P/c15-9-10(16)13-8-5(3-11-4-22(19,20)21)1-6(14(17)18)2-7(8)12-9/h1-2,11H,3-4H2,(H,12,15)(H,13,16)(H2,19,20,21) Key:ABFMMCZFKUIJGQ-UHFFFAOYSA-N

Becampanel (INN) (code name AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor (IC₅₀ = 11 nM).^[1][2][3][4] It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials.^[1][2][3][5]

See also

• Perampanel
• Selurampanel
• Talampanel

References

1. John B. Taylor; D. J. Triggle (2007). Comprehensive medicinal chemistry II. Elsevier. p. 290. ISBN 978-0-08-044513-7.
2. Kwan P, Brodie MJ (September 2007). "Emerging drugs for epilepsy". Expert Opin Emerg Drugs 12 (3): 407–22. doi:10.1517/14728214.12.3.407. PMID 17874969.
3. Citraro R, Aiello R, Franco V, De Sarro G, Russo E (March 2014). "Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy". Expert Opin. Ther. Targets 18 (3): 319–34. doi:10.1517/14728222.2014.874416. PMID 24387310.
4. World Health Organization (1988). International Nonproprietary Names (INN) for Pharmaceutical Substances. W.H.O.
5. Pathan SA, Jain GK, Akhter S, Vohora D, Ahmad FJ, Khar RK (September 2010). "Insights into the novel three 'D's of epilepsy treatment: drugs, delivery systems and devices". Drug Discov. Today 15 (17-18): 717–32. doi:10.1016/j.drudis.2010.06.014. PMID 20603226.